Tyra Biosciences Business Summary

Tyra Biosciences, Inc. (TYRA) is a clinical-stage biotechnology company specializing in the development of next-generation precision medicines through its proprietary SNAP platform. The company’s business model is centered on drug discovery and clinical advancement rather than immediate product sales, with current revenue primarily derived from potential future licensing, milestone payments, or commercialization of its pipeline. TYRA’s primary business segments focus on targeting Fibroblast Growth Factor Receptor (FGFR) biology to address acquired drug resistance in oncology and genetically defined conditions, such as skeletal dysplasias. Its lead candidate, dabogratinib (TYRA-300), is currently in Phase 2 clinical trials for achondroplasia and urologic cancers. Within the competitive landscape, Tyra contends with other precision medicine and oncology-focused firms such as Relay Therapeutics, Kymera Therapeutics, and Cogent Biosciences, positioning itself as a specialist in overcoming structural resistance mutations that render first-generation FGFR inhibitors ineffective. The company is led by a management team with extensive pedigree in biopharmaceutical development and commercialization. Co-founder and CEO Todd Harris previously co-founded Sienna Biopharmaceuticals and served as a consultant at McKinsey & Company, while Co-founder and COO Daniel Bensen formerly led immunology efforts at Cidara Therapeutics. The executive suite was significantly bolstered in late 2024 and 2025 with the appointments of Chief Medical Officer Doug Warner, M.D., an 18-year Amgen veteran, and Chief Operating Officer Bhavesh Ashar, who previously served as Chief Commercial Officer at SpringWorks Therapeutics and led U.S. Oncology at Bayer. Financial leadership is provided by CFO Alan Fuhrman, a veteran executive with prior roles at Amplyx and Loxo Oncology. Tyra is backed by a sophisticated syndicate of institutional investors and board members, including representatives from Alta Partners, RA Capital Management, Boxer Capital, and Nextech Invest.